These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29410009)

  • 1. Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia.
    Lin Y; Peng Y; He S; Xu J; Shi Y; Su Y; Zhu C; Zhang X; Zhou R; Cui D
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):71-78. PubMed ID: 29410009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia.
    Tsuneyama N; Suzuki Y; Sawamura K; Sugai T; Fukui N; Watanabe J; Ono S; Saito M; Someya T
    PLoS One; 2016; 11(3):e0149518. PubMed ID: 26930407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.
    Melkersson KI; Hulting AL; Brismar KE
    J Clin Psychiatry; 2000 Oct; 61(10):742-9. PubMed ID: 11078035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Clinical Correlation between Insulin Resistance and Antipsychotic Drug Therapy in Patients with Schizophrenia.
    Wang F; Wang F; Tao X; Ni W; Li W; Lin J
    Actas Esp Psiquiatr; 2024 Aug; 52(4):412-419. PubMed ID: 39129685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia.
    Klemettilä JP; Kampman O; Seppälä N; Viikki M; Hämäläinen M; Moilanen E; Mononen N; Lehtimäki T; Leinonen E
    Eur Psychiatry; 2015 Feb; 30(2):296-302. PubMed ID: 25284335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 6-week olanzapine treatment on serum IL-2, IL-4, IL-8, IL-10, and TNF-α levels in drug-naive individuals with first-episode schizophrenia.
    Zhao X; Zhu W; Bu Y; Li J; Hao Y; Bi Y
    BMC Psychiatry; 2024 Oct; 24(1):703. PubMed ID: 39425118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia.
    Baptista T; Dávila A; El Fakih Y; Uzcátegui E; Rangel NN; Olivares Y; Galeazzi T; Vargas D; Peña R; Marquina D; Villarroel V; Teneud L; Beaulieu S
    Int Clin Psychopharmacol; 2007 Jul; 22(4):205-11. PubMed ID: 17519643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.
    Hosojima H; Togo T; Odawara T; Hasegawa K; Miura S; Kato Y; Kanai A; Kase A; Uchikado H; Hirayasu Y
    J Psychopharmacol; 2006 Jan; 20(1):75-9. PubMed ID: 16204328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine.
    Klemettilä JP; Kampman O; Seppälä N; Viikki M; Hämäläinen M; Moilanen E; Leinonen E
    Psychiatry Res; 2014 Aug; 218(3):277-83. PubMed ID: 24837425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
    Ono S; Sugai T; Suzuki Y; Yamazaki M; Shimoda K; Mori T; Ozeki Y; Matsuda H; Sugawara N; Yasui-Furukori N; Okamoto K; Sagae T; Someya T
    BMC Psychiatry; 2018 Jun; 18(1):180. PubMed ID: 29879941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients.
    Sirota P; Meiman M; Herschko R; Bessler H
    Psychiatry Res; 2005 Apr; 134(2):151-9. PubMed ID: 15840416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
    Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
    Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia.
    Sugai T; Suzuki Y; Fukui N; Ono S; Watanabe J; Tsuneyama N; Someya T
    J Clin Psychopharmacol; 2012 Jun; 32(3):390-3. PubMed ID: 22544005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.
    Konarzewska B; Waszkiewicz N; Galińska B; Szulc A
    Neuro Endocrinol Lett; 2013; 34(4):322-8. PubMed ID: 23803867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.
    Suzuki Y; Ono S; Sugai T; Fukui N; Watanabe J; Tsuneyama N; Sawamura K; Someya T
    Hum Psychopharmacol; 2011 Aug; 26(6):440-3. PubMed ID: 21823168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study.
    Zhang Y; Fang X; Fan W; Tang W; Cai J; Song L; Zhang C
    Psychopharmacology (Berl); 2018 Apr; 235(4):1191-1198. PubMed ID: 29392373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia.
    Lu ML; Chen CH; Kuo PT; Lin CH; Wu TH
    Schizophr Res; 2018 Mar; 193():139-145. PubMed ID: 28720417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein-Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study.
    Shen H; Wu D; Wang S; Zhao M; Sun W; Zhu X; Zhang N; Yao H; Cui Q; Xiao H
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):756-765. PubMed ID: 29938908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.